Grant: Operating Grant: Women's Health Clinical Mentorship Grant
University of British Columbia
$50,000.00
Women Living with HIV: Severity and Treatment of Menopausal Symptoms
EF 2019-20
Résumé
People living with HIV across the world are aging. In 2030, it is estimated that ~70% of individuals with HIV will be over 50 years. In conjunction with this evolving landscape of HIV, the UNAIDS has called for a "new worldwide focus on persons living with HIV aged 50 or older." For women living with HIV (WLWH), one of the most important life events nearing this age is that of menopause, a time accompanied by changes in physiology that affect quality of life and aging processes. Preliminary research suggests that WLWH experience menopause differently than HIV-negative peers and some studies suggest symptoms are heightened and undertreated in WLWH compared to the general population. Key knowledge gaps exist in understanding menopausal symptoms in WLWH including their evolution, biologic basis and management. All of these gaps serve as barriers to provision of optimal patient-centred care for WLWH.
To further understand the menopausal experience in HIV, we will conduct a series of studies using 2 large cohorts of Canadian WLWH throughout stages of menopause. We will assess menopausal symptoms and follow their progression longitudinally. We will then assess hormonal changes throughout menopause, comparing important sex hormone levels (such as estrogen) during the menopausal transition compared to controls, and relate these hormones to symptom experience. Finally, we will evaluate the largest population of menopause hormone therapy used in WLWH in order to elicit characteristics of and barriers to use, thereby adding to the limited collective experience of hormonal therapy use in HIV.
It is imperative moving forward that health providers adopt a tailored approach to address the complexities of reproductive health in HIV care. Further elucidating differences in the menopause experience in HIV from its progression and hormonal basis to treatment implications is a crucial step toward adopting a holistic approach to one of life's most important transitions.
Programme
Operating Grant: Women's Health Clinical Mentorship Grant
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
415569
Name
Murray Melanie C
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Clinical
Prcname2
Women's Health Clinical Mentorship Grant
Projecttitle
Women Living with HIV: Severity and Treatment of Menopausal Symptoms
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
Operating Grant: Women's Health Clinical Mentorship Grant
Keyworddelim
Aging; Hiv; Menopause; Women
Abstract
People living with HIV across the world are aging. In 2030, it is estimated that ~70% of individuals with HIV will be over 50 years. In conjunction with this evolving landscape of HIV, the UNAIDS has called for a "new worldwide focus on persons living with HIV aged 50 or older." For women living with HIV (WLWH), one of the most important life events nearing this age is that of menopause, a time accompanied by changes in physiology that affect quality of life and aging processes. Preliminary research suggests that WLWH experience menopause differently than HIV-negative peers and some studies suggest symptoms are heightened and undertreated in WLWH compared to the general population. Key knowledge gaps exist in understanding menopausal symptoms in WLWH including their evolution, biologic basis and management. All of these gaps serve as barriers to provision of optimal patient-centred care for WLWH.
To further understand the menopausal experience in HIV, we will conduct a series of studies using 2 large cohorts of Canadian WLWH throughout stages of menopause. We will assess menopausal symptoms and follow their progression longitudinally. We will then assess hormonal changes throughout menopause, comparing important sex hormone levels (such as estrogen) during the menopausal transition compared to controls, and relate these hormones to symptom experience. Finally, we will evaluate the largest population of menopause hormone therapy used in WLWH in order to elicit characteristics of and barriers to use, thereby adding to the limited collective experience of hormonal therapy use in HIV.
It is imperative moving forward that health providers adopt a tailored approach to address the complexities of reproductive health in HIV care. Further elucidating differences in the menopause experience in HIV from its progression and hormonal basis to treatment implications is a crucial step toward adopting a holistic approach to one of life's most important transitions.
Competitiondate
201910
Approvedterm2
1 yr 0 mth
Pinamesdelim
Murray, Melanie C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $50,000~ $0~